Mineralys Therapeutics, Inc. 8-K

What Happened
Mineralys Therapeutics, Inc. (MLYS) filed an 8-K reporting the results of its annual meeting of stockholders held May 21, 2026. Stockholders elected three Class III directors to three‑year terms (expiring at the 2029 annual meeting) and ratified Ernst & Young LLP as the company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. Both proposals received the requisite shareholder approval.

Key Details

• Meeting date: May 21, 2026; proxy statement describing the proposals filed April 8, 2026.
• Director votes:
  • Srinivas Akkaraju, M.D., Ph.D.: For 40,667,555; Withhold 26,447,538; Broker non‑votes 5,569,960.
  • Brian Taylor Slingsby, M.D., Ph.D., M.P.H.: For 42,487,140; Withhold 24,627,953; Broker non‑votes 5,569,960.
  • Daphne Karydas: For 66,626,766; Withhold 488,327; Broker non‑votes 5,569,960.
• Auditor ratification (Proposal 2): Ernst & Young LLP — For 72,648,272; Against 9,516; Abstain 27,265; Broker non‑votes 0.

Why It Matters
These are governance outcomes that affect who will oversee company strategy and financial reporting. The elected directors will serve through 2029, providing board continuity. Ratification of Ernst & Young LLP confirms the auditor for FY 2026, which matters for the company’s upcoming audited financial statements. Broker non‑votes on the director elections show some shares held in street name did not participate in those votes, which can influence vote margins but did not prevent approval.